FTC Reaches Settlement with Private Equity Firm Over Antitrust Allegations in Texas

The Federal Trade Commission (FTC) announced on Friday that it has reached a settlement with Welsh, Carson, Anderson & Stowe and its affiliates over allegations that the private equity firm engaged in practices suppressing competition in the anesthesiology services market in Texas.
According to Reuters, the FTC claimed that Welsh Carson, a New York-based firm, utilized its portfolio company, U.S. Anesthesia Partners, to acquire numerous anesthesia practices in the state, consolidating them into a dominant entity capable of commanding higher prices.
The allegations echoed those in a lawsuit filed by the FTC last year in federal court against Welsh Carson and U.S. Anesthesia Partners. That case was dismissed by a judge in May 2023. Welsh Carson denied any wrongdoing in connection with the claims, criticizing the FTC’s approach in its Friday statement.
According to Reuters, the firm characterized the FTC’s actions as a last-minute attempt to revisit previously dismissed allegations and secure a settlement ahead of the second term of Republican President-elect Donald Trump.
Republican FTC Commissioner Andrew Ferguson, who has been nominated to lead the agency, described the case as “an ordinary application of the most elementary antitrust principles,” per Reuters.
As part of the settlement, Welsh Carson agreed to reduce its involvement with U.S. Anesthesia Partners. The firm will now be limited to a single seat on the company’s board and will require FTC approval for any future investments in anesthesia practices.
Source: Reuters
Featured News
Federal Appeals Court Temporarily Halts Ruling in Consumer Bureau Battle
Apr 3, 2025 by
CPI
Capital One-Discover $35 Billion Merger Moves Forward After DOJ Decision
Apr 3, 2025 by
CPI
RealPage Sues Berkeley Over Ban on Rental Pricing Software
Apr 3, 2025 by
CPI
Olivia Trusty’s FCC Nomination Set for Senate Hearing Next Week
Apr 3, 2025 by
CPI
Amazon Challenges France’s Book Delivery Fee at EU Court
Apr 3, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition: Year of the Snake
Apr 3, 2025 by
CPI
The Fair Competition Review and the Unified National Market in China
Apr 3, 2025 by
Sen La & Wei Han
Facing the Conundrums: China’s Antitrust Policy Amid Geopolitical Shifts
Apr 3, 2025 by
Da Shi
Concentrations in China in 2023 and 2024
Apr 3, 2025 by
John Yong Ren, Karen Mei & Martha Shu Wen
SAMR’s Evolving Role on the Geopolitical Chessboard
Apr 3, 2025 by
Andrew Foster, Danette Chan & Flora Xiao